A detailed history of Lindbrook Capital, LLC transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 114 shares of RCKT stock, worth $1,593. This represents 0.0% of its overall portfolio holdings.

Number of Shares
114
Previous 217 47.47%
Holding current value
$1,593
Previous $4,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$17.6 - $25.88 $1,812 - $2,665
-103 Reduced 47.47%
114 $2,000
Q2 2024

Jul 31, 2024

BUY
$20.66 - $26.72 $888 - $1,148
43 Added 24.71%
217 $4,000
Q1 2024

Apr 25, 2024

BUY
$26.16 - $30.74 $130 - $153
5 Added 2.96%
174 $4,000
Q4 2023

Jan 31, 2024

SELL
$16.78 - $31.94 $234 - $447
-14 Reduced 7.65%
169 $5,000
Q3 2023

Oct 25, 2023

BUY
$15.07 - $24.05 $1,431 - $2,284
95 Added 107.95%
183 $3,000
Q2 2022

Aug 01, 2022

BUY
$7.96 - $16.64 $700 - $1,464
88 New
88 $1,000
Q2 2021

Jul 27, 2021

SELL
$39.41 - $47.25 $9,300 - $11,151
-236 Closed
0 $0
Q1 2021

Apr 28, 2021

SELL
$43.34 - $65.91 $59,115 - $89,901
-1,364 Reduced 85.25%
236 $10,000
Q4 2020

Jan 27, 2021

SELL
$23.3 - $59.57 $2,330 - $5,957
-100 Reduced 5.88%
1,600 $88,000
Q3 2020

Nov 03, 2020

BUY
$20.5 - $28.59 $34,850 - $48,603
1,700 New
1,700 $39,000
Q2 2020

Jul 27, 2020

SELL
$13.32 - $22.61 $19,980 - $33,915
-1,500 Closed
0 $0
Q4 2019

Jan 27, 2020

SELL
$11.07 - $24.23 $16,605 - $36,345
-1,500 Reduced 50.0%
1,500 $34,000
Q3 2019

Oct 31, 2019

BUY
$10.85 - $14.78 $21,700 - $29,560
2,000 Added 200.0%
3,000 $35,000
Q2 2019

Jul 24, 2019

BUY
$15.0 - $19.81 $15,000 - $19,810
1,000 New
1,000 $15,000
Q1 2019

Apr 23, 2019

SELL
$13.45 - $19.01 $6,725 - $9,505
-500 Closed
0 $0
Q4 2018

Feb 07, 2019

BUY
$11.21 - $23.53 $5,605 - $11,765
500 New
500 $7,000

Others Institutions Holding RCKT

About ROCKET PHARMACEUTICALS, INC.


  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $1.06B
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.